Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.30 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.30 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5961066 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRTDP1LPAR3LPAR1 | |
| SCHEMBL5961013 | 0.98 | ALDH1A1 (0.36) | ALDH1A1TSHRTDP1CYP4F2CYP4A11 | |
| SCHEMBL5961124 | 0.91 | ALDH1A1 (0.38) | ALDH1A1TSHRTDP1 | |
| SCHEMBL5961031 | 0.83 | — | — | |
| SCHEMBL5961061 | 0.83 | — | — | |
| SCHEMBL4819592 | 0.83 | — | — | |
| SCHEMBL7149797 | 0.82 | CES2 (0.31) | LPAR3LPAR1LPAR2CYP4F2CYP4A11 | |
| SCHEMBL24400073 | 0.81 | ALDH1A1 (0.38) | ALDH1A1TSHRTDP1 | |
| SCHEMBL8024586 | 0.81 | LPAR3 (0.41) | ALDH1A1TSHRTDP1LPAR3LPAR1 | |
| SCHEMBL20476803 | 0.81 | LPAR3 (0.41) | ALDH1A1TSHRTDP1LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39088-E1 | Amide compounds and use of the same | JAPAN TOBACCO, INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| WO-2005082459-A2 | METHOD OF DECREASING BLOOD CELLS | JAPAN TOBACCO INC. (JP) | 2005-09-09 | — | — | WO | disclosed |
| US-20050187221-A1 | Method of treating ischemia reperfusion injury | JAPAN TOBACCO INC. (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-0849256-B1 | AMIDE COMPOUNDS AND USE OF THE SAME | JAPAN TOBACCO INC (JP) | 2005-06-08 | — | — | EP | disclosed |
| EP-1304322-A2 | Carboxylic acid compound and use thereof | Japan Tobacco Inc. (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6420561-B1 | Amide compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-6174887-B1 | Amide compounds and use of the same | JAPAN TOBACCO INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| US-6015921-A | Process for producing carbamoylmethylurea derivatives | SHIONOGI & CO., LTD. (JP) | 2000-01-18 | — | — | US | disclosed |
| EP-0849256-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | Japan Tobacco Inc. (JP) | 1998-06-24 | — | — | EP | disclosed |
| EP-0495610-B1 | Tetrahydroisoquinoline derivatives, processes for producing the same and fungicides containing the same | TOSOH CORP (JP) | 1997-06-18 | — | — | EP | disclosed |
| EP-0669912-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-06 | — | — | EP | disclosed |
| EP-0495610-A1 | Tetrahydroisoquinoline derivatives, processes for producing the same and fungicides containing the same | TOSOH CORPORATION (JP) | 1992-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187221-A1 | Method of treating ischemia reperfusion injury | TNF, IL1B, TNNI3 | ALDH1A1 358/4885TSHR 2648/4885TDP1 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.